SeaBeLifeSeabelife SAS to develop next-gen dry AMD drug
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Seabelife SAS to develop next-gen dry AMD drug
/in News/by Thomas GabrielczykFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
AmphiStar BV secures €6m to expand production
/in News/by Thomas GabrielczykWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Naobios and Sumagen partner to develop HIV vaccine
/in News/by Thomas GabrielczykVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.<br /> <br /><b><br /></b>
Solar Foods starts Factory01
/in News/by Thomas GabrielczykFinnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
Shock: Adrenomed AG gets FDA fast track designation
/in News/by Thomas GabrielczykGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. <br /><br /><br /><br />
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
/in News/by Thomas GabrielczykALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Essential Pharma acquires Renaissance Pharma Ltd
/in News/by Thomas GabrielczykEssential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.<br /><br />
Unitaid awards Medincell US$6m to fight malaria
/in News/by Thomas GabrielczykGlobal health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine […]
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
/in News/by Thomas GabrielczykGenmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline […]